Retatrutide: The Triple-Agonist That Lost Patients 71 Pounds in Trials

Retatrutide (LY3437943) is the most powerful weight loss medication ever tested in clinical trials. Developed by Eli Lilly, this investigational triple-agonist drug activates three metabolic hormone receptors simultaneously — GLP-1, GIP, and glucagon — producing weight loss results that surpass every existing treatment. In Phase 2 trials published in the New England Journal of Medicine, patients on the highest dose lost an average of 24.2% of their body weight in just 48 weeks. For someone weighing 295 pounds, that translates to roughly 71 pounds lost.

What Is Retatrutide?

Retatrutide is an investigational injectable peptide drug being developed by Eli Lilly and Company for the treatment of obesity and type 2 diabetes. Its internal designation is LY3437943. Unlike semaglutide (Wegovy/Ozempic), which targets only the GLP-1 receptor, or tirzepatide (Mounjaro/Zepbound), which targets both GLP-1 and GIP receptors, retatrutide is the first drug to simultaneously activate all three incretin and metabolic hormone receptors: GLP-1, GIP, and glucagon.

This triple-agonist approach represents the most advanced evolution of the incretin-based weight loss drug class. Each additional receptor target appears to unlock greater weight loss efficacy. Semaglutide (one receptor) produces roughly 15% body weight loss. Tirzepatide (two receptors) reaches approximately 22%. Retatrutide (three receptors) has achieved nearly 25% — and weight loss was still accelerating when the Phase 2 trial ended at 48 weeks.

The Triple Mechanism: GLP-1 + GIP + Glucagon

Understanding why retatrutide works so well requires understanding each of its three receptor targets and how they complement each other.

GLP-1 (Glucagon-Like Peptide-1) Receptor

GLP-1 receptor activation is the foundation shared by all modern weight loss drugs. When stimulated, GLP-1 receptors reduce appetite by acting on hunger centers in the hypothalamus and brainstem, slow gastric emptying to increase satiety after meals, improve insulin sensitivity and glucose-dependent insulin secretion, and reduce food reward signaling. This receptor alone is responsible for the effectiveness of semaglutide, which produces 14.9% average weight loss in the STEP trials.

GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor

Adding GIP receptor activation was the innovation behind tirzepatide. GIP contributes by enhancing insulin secretion beyond what GLP-1 achieves alone, improving lipid metabolism and fat tissue remodeling, increasing the tolerability of GLP-1 effects (particularly nausea), and potentially improving bone metabolism. The combination of GLP-1 and GIP in tirzepatide bumps average weight loss from approximately 15% to 22.5% — a significant improvement over GLP-1 alone.

Glucagon Receptor: The Third Target

Glucagon receptor activation is what makes retatrutide unique. While it may seem counterintuitive — glucagon raises blood sugar and is often viewed as insulin's opponent — its metabolic effects provide critical additional weight loss mechanisms. Glucagon receptor activation increases hepatic energy expenditure by stimulating liver thermogenesis, promotes lipolysis (fat breakdown) in adipose tissue, increases metabolic rate by 10-15% beyond what GLP-1 and GIP achieve, reduces hepatic fat content (liver fat), and suppresses appetite through central nervous system pathways independent of GLP-1.

The glucagon component is the key innovation. While GLP-1 and GIP primarily reduce caloric intake by suppressing appetite, glucagon increases caloric output by boosting energy expenditure. Retatrutide attacks obesity from both sides of the energy equation — less energy in, more energy out. This dual-sided approach likely explains the unprecedented weight loss results.

Phase 2 Clinical Trial Results

The landmark Phase 2 trial of retatrutide was published by Jastreboff et al. in the New England Journal of Medicine in June 2023. This randomized, double-blind, placebo-controlled trial enrolled 338 adults with obesity (BMI of 30 or higher) or overweight (BMI of 27 or higher with at least one weight-related comorbidity) across multiple sites. Participants were randomized to receive one of several retatrutide doses (1 mg, 4 mg, 8 mg, or 12 mg) or placebo, administered as weekly subcutaneous injections for 48 weeks.

Weight Loss Results by Dose

The results are striking at every dose level, but the 12 mg group stands out. An average weight loss of 24.2% at 48 weeks means a person starting at 295 pounds dropped to roughly 224 pounds — a 71-pound reduction. Perhaps even more remarkable: 26% of participants in the highest dose group lost more than 30% of their body weight, approaching the results typically seen only with bariatric surgery.

Critically, weight loss curves in the Phase 2 trial had not plateaued at 48 weeks. Participants were still losing weight when the study ended, suggesting that longer treatment periods could yield even greater reductions. This is being tested in the Phase 3 TRIUMPH program.

The TRIUMPH Phase 3 Program

Eli Lilly launched the TRIUMPH Phase 3 clinical trial program for retatrutide in late 2023. This large-scale program includes several pivotal trials designed to establish retatrutide's efficacy and safety for FDA approval. The TRIUMPH program includes trials for obesity and overweight in adults without diabetes, obesity in adults with type 2 diabetes, long-term cardiovascular outcomes, and studies in specific populations including those with obstructive sleep apnea.

Phase 3 trials typically enroll thousands of participants across hundreds of clinical sites and run for 52 to 68 weeks or longer. These trials will provide the large-scale safety and efficacy data the FDA requires to evaluate a New Drug Application (NDA). Based on current timelines, TRIUMPH data readouts are expected in late 2025 through 2026, with an NDA submission potentially following in 2026 and FDA approval possible by late 2026 or 2027.

How Retatrutide Compares to Current Treatments

What 71 Pounds of Weight Loss Actually Means

Clinical trial percentages can feel abstract. To understand what 24.2% weight loss means in real life, consider what it represents for a person at the average baseline weight in the trial (approximately 295 pounds or 134 kg). A 71-pound weight loss moves most participants from Class II or III obesity (BMI 35-40+) into the overweight or normal-weight range. It is associated with significant improvements in blood pressure, cholesterol, blood sugar control, and inflammation markers. It dramatically reduces risk of type 2 diabetes, cardiovascular disease, and certain cancers. It often resolves obstructive sleep apnea and improves joint pain. It improves mobility, energy levels, and quality of life across nearly every measurable dimension.

To put it in surgical terms, this level of weight loss approaches what was previously achievable only through Roux-en-Y gastric bypass surgery, which typically produces 25-35% weight loss. Retatrutide is bringing surgery-level results to a weekly injection.

Timeline to Availability

Retatrutide is not yet available for prescription. Here is the expected timeline based on publicly available information from Eli Lilly and standard FDA processes:

• 2023-2024: Phase 3 TRIUMPH trials enrolled and ongoing
• Late 2025 - Mid 2026: Phase 3 data readouts expected
• 2026: Potential NDA submission to FDA
• Late 2026 - 2027: Potential FDA approval (standard review takes 10-12 months; priority review takes 6 months)
• 2027: Earliest likely commercial availability

These timelines are estimates and could shift based on trial results, manufacturing readiness, and FDA review decisions. Eli Lilly has experience navigating this process efficiently — they brought tirzepatide from Phase 3 to approval in approximately 18 months.

What You Can Do Now

While retatrutide is not yet available, highly effective treatments exist today. Trimi offers both semaglutide and tirzepatide — the two most effective FDA-approved weight loss medications currently available. For patients who want to begin their weight loss journey now, starting with semaglutide or tirzepatide provides meaningful results while the next generation of treatments works through the approval process.

Many patients find that starting treatment sooner rather than later is beneficial. Weight loss with current medications improves metabolic health, and patients who have already established a treatment relationship will be well-positioned to transition to retatrutide when it becomes available. Learn how Trimi's telehealth platform works to get started today.

Frequently Asked Questions

What is retatrutide?

Retatrutide (LY3437943) is an investigational injectable weight loss drug developed by Eli Lilly. It is a triple agonist that activates three hormone receptors: GLP-1, GIP, and glucagon. In Phase 2 clinical trials, it produced an average weight loss of 24.2% of body weight at the highest dose — the most of any drug ever tested for obesity.

How much weight can you lose with retatrutide?

In the Phase 2 trial, the 12 mg dose produced an average weight loss of 24.2% over 48 weeks. For the average participant weighing 295 pounds at baseline, this equated to approximately 71 pounds lost. Over a quarter of participants lost more than 30% of their body weight.

When will retatrutide be FDA-approved?

Retatrutide is currently in Phase 3 trials (the TRIUMPH program). Based on typical development timelines, FDA approval could come in late 2026 or 2027, though this depends on trial results and the regulatory review process.

How is retatrutide different from Ozempic or Mounjaro?

Ozempic (semaglutide) activates one receptor (GLP-1). Mounjaro (tirzepatide) activates two (GLP-1 + GIP). Retatrutide activates three (GLP-1 + GIP + glucagon). Each additional receptor target has been associated with greater weight loss in clinical trials.

What are the side effects of retatrutide?

Phase 2 data showed side effects similar to other GLP-1-based drugs, primarily gastrointestinal symptoms: nausea, diarrhea, vomiting, and constipation. These were generally mild to moderate and tended to decrease over time. The glucagon component requires monitoring of liver function and blood glucose. Read our detailed retatrutide side effects guide for full Phase 3 data.

Can I get retatrutide now?

Retatrutide is not yet available outside of clinical trials. However, Trimi offers semaglutide and tirzepatide, which are the most effective FDA-approved weight loss medications currently available. Starting treatment now allows you to begin losing weight while next-generation drugs work through the approval process.